Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CYTOGEN WILL LAUNCH ONCOSCINT CR/OV "WITHIN THE NEXT 30 DAYS"

This article was originally published in The Gray Sheet

Executive Summary

CYTOGEN WILL LAUNCH ONCOSCINT CR/OV "WITHIN THE NEXT 30 DAYS," Chairman and CEO George Ebright reported at a Jan. 5 press conference. The monoclonal antibody-based imaging agent was approved Dec. 29 for the imaging of known colorectal and ovarian cancers ("The Gray Sheet" Jan. 4, p. 15). Cytogen's fourth quarter losses will be less than anticipated as a result of the end-of-year approval. On Dec. 31, Cytogen released estimated results for the 1992 fiscal year (ended Jan. 2) that include a one-time, $2 mil. milestone payment from Knoll Pharmaceuticals, which will co-promote OncoScint (satumomab pendetide) with Cytogen. The company estimates its net loss for the fourth quarter of 1992 at $2.6 mil., down from a $3.1 mil. loss in 1991. The 1991 fourth quarter results included a $1.6 mil. non-recurrent, one- time charge. Revenues are estimated to be $4.8 mil. in the fourth quarter, as compared to $5 mil. in 1991. Revenues for all of 1992 are expected to be up 51% to $16.5 mil. Net loss for 1992 is estimated at $12.9 mil., compared to $15.3 mil. in 1991.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT000041

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel